

John D Minna

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6116638/john-d-minna-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

277
papers

29,633
citations

84
h-index

170
g-index

300
ext. papers

34,192
ext. citations

11.7
avg, IF

6.54
L-index

#	Paper	IF	Citations
277	Establishment of reference standards for multifaceted mosaic variant analysis.. <i>Scientific Data</i> , 2022 , 9, 35	8.2	
276	Resistance to mutant KRAS-induced senescence in a hTERT/Cdk4-immortalized normal human bronchial epithelial cell line.. <i>Experimental Cell Research</i> , 2022 , 113053	4.2	
275	AP-1 leads the way in lung cancer transformation.. <i>Developmental Cell</i> , 2022 , 57, 292-294	10.2	0
274	Unbiased peptoid cell screen identifies a peptoid targeting newly appeared cell surface vimentin on tumor transformed early lung cancer cells.. <i>Bioorganic and Medicinal Chemistry</i> , 2022 , 58, 116673	3.4	1
273	AXL targeting restores PD-1 blockade sensitivity of mutant NSCLC through expansion of TCF1 CD8 T cells.. <i>Cell Reports Medicine</i> , 2022 , 3, 100554	18	4
272	Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy. <i>Cancer Cell</i> , 2021 , 39, 1455-1457	24.3	
271	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	3
270	Phosphatidylserine receptors enhance SARS-CoV-2 infection. <i>PLoS Pathogens</i> , 2021 , 17, e1009743	7.6	10
269	602 AXL targeting with bemcentinib restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells 2021 , 9, A632-A632		
268	Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. <i>Nature Communications</i> , 2021 , 12, 7014	17.4	0
267	Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. <i>Molecular Cancer Research</i> , 2021 ,	6.6	2
266	Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology 2021 ,		15
265	Single-Cell Expression Landscape of SARS-CoV-2 Receptor and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4
264	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. <i>Cancer Cell</i> , 2021 , 39, 346-360.e7	24.3	107
263	Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. <i>Communications Biology</i> , 2021 , 4, 314	6.7	9
262	A rational targeted therapy for platinum-resistant small-cell lung cancer. <i>Cancer Cell</i> , 2021 , 39, 453-456	24.3	2
261	SH3BP4 promotes neuropilin-1 and β -integrin endocytosis and is inhibited by Akt. <i>Developmental Cell</i> , 2021 , 56, 1164-1181.e12	10.2	2

260	Phosphatidylserine Receptors Enhance SARS-CoV-2 Infection: AXL as a Therapeutic Target for COVID-19 2021 ,		7
259	Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3351-3368	4.4	
258	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1821-1839	8.9	8
257	Altered Regulation of HIF-1 α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 439-451	8.9	11
256	A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021 , 11, 240-244	24.4	2
255	Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	15
254	Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis. <i>Cancer Research</i> , 2021 , 81, 1813-1826	10.1	14
253	Elevated NSD3 histone methylation activity drives squamous cell lung cancer. <i>Nature</i> , 2021 , 590, 504-508	30.4	27
252	Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression. <i>Science Advances</i> , 2021 , 7,	14.3	56
251	Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. <i>Cancer Research</i> , 2021 , 81, 4685-4695	10.1	2
250	Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers. <i>Cancer Research</i> , 2021 , 81, 3441-3443	10.1	
249	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2051-2064	8.9	1
248	Dual targeting of CTLA-4 and CD47 on T cells promotes immunity against solid tumors. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	8
247	ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer. <i>iScience</i> , 2021 , 24, 102953	6.1	3
246	Co-immunoprecipitation and semi-quantitative immunoblotting for the analysis of protein-protein interactions. <i>STAR Protocols</i> , 2021 , 2, 100644	1.4	3
245	The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis.. <i>Cancers</i> , 2021 , 13,	6.6	2
244	An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis. <i>Neoplasia</i> , 2020 , 22, 294-310	6.4	5
243	Immortalized normal human lung epithelial cell models for studying lung cancer biology. <i>Respiratory Investigation</i> , 2020 , 58, 344-354	3.4	8

242	Is a Biomarker of Sensitivity to the Telomeric DNA Damage Mediator 6-Thio-2-Deoxyguanosine. <i>Cancer Research</i> , 2020 , 80, 929-936	10.1	4
241	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 520-540	8.9	42
240	Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers. <i>Cancer Science</i> , 2020 , 111, 610-620	6.9	7
239	Computational Staining of Pathology Images to Study the Tumor Microenvironment in Lung Cancer. <i>Cancer Research</i> , 2020 , 80, 2056-2066	10.1	27
238	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 973-999	8.9	36
237	eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. <i>Nature Cancer</i> , 2020 , 1, 533-545	15.4	35
236	EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. <i>Nature Cancer</i> , 2020 , 1, 394-409	15.4	17
235	Elucidating Mechanisms of Acquired Resistance to IDH Inhibition By Saturation Variant Screening of Base-Edited Leukemia Cells. <i>Blood</i> , 2020 , 136, 3-3	2.2	
234	FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells. <i>American Journal of Translational Research (discontinued)</i> , 2020 , 12, 409-427	3	5
233	KRT-232 and navitoclax enhance trametinib anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. <i>American Journal of Cancer Research</i> , 2020 , 10, 4464-4475	4.4	3
232	Mechanical regulation of glycolysis via cytoskeleton architecture. <i>Nature</i> , 2020 , 578, 621-626	50.4	137
231	RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. <i>Cell Chemical Biology</i> , 2020 , 27, 105-121.e14	8.2	14
230	A Proteomic Connectivity Map for Characterizing the Tumor Adaptive Response to Small Molecule Chemical Perturbagens. <i>ACS Chemical Biology</i> , 2020 , 15, 140-150	4.9	5
229	Defining the First Part of the Oncogenic KRAS Journey. <i>Cell Stem Cell</i> , 2020 , 27, 499-500	18	1
228	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. <i>Cell Reports</i> , 2020 , 33, 108296	10.6	32
227	The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. <i>Nature Metabolism</i> , 2020 , 2, 1401-1412	14.6	26
226	Studying Lineage Plasticity One Cell at a Time. <i>Cancer Cell</i> , 2020 , 38, 150-152	24.3	5
225	Molecular differences across invasive lung adenocarcinoma morphological subgroups. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1029-1040	4.4	1

224	Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?. <i>EBioMedicine</i> , 2020 , 60, 103006	8.8	
223	Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. <i>Molecular Cell</i> , 2019 , 76, 838-851.e5	17.6	51
222	Development and Validation of a Pathology Image Analysis-based Predictive Model for Lung Adenocarcinoma Prognosis - A Multi-cohort Study. <i>Scientific Reports</i> , 2019 , 9, 6886	4.9	4
221	LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in -Mutant Lung Adenocarcinoma. <i>Cancer Research</i> , 2019 , 79, 3251-3267	10.1	103
220	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. <i>Nature Reviews Cancer</i> , 2019 , 19, 289-297	31.3	304
219	p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. <i>Cell Reports</i> , 2019 , 28, 1860-1878.e9	10.6	35
218	Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells. <i>Nature Communications</i> , 2019 , 10, 3201	17.4	10
217	Systematic Analysis of Gene Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma with a Case Study of and. <i>Cancers</i> , 2019 , 11,	6.6	5
216	ClickGene: an open cloud-based platform for big pan-cancer data genome-wide association study, visualization and exploration. <i>BioData Mining</i> , 2019 , 12, 12	4.3	8
215	AIF: an acquired metabolic liability in lung cancer. <i>Cell Research</i> , 2019 , 29, 607-608	24.7	
214	Unbiased peptoid combinatorial cell screen identifies plectin protein as a potential biomarker for lung cancer stem cells. <i>Scientific Reports</i> , 2019 , 9, 14954	4.9	17
213	Artificial Intelligence in Lung Cancer Pathology Image Analysis. <i>Cancers</i> , 2019 , 11,	6.6	58
212	From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. <i>Journal of Cellular Biochemistry</i> , 2019 , 121, 3986	4.7	3
211	Small cell lung cancers made from scratch. <i>Journal of Experimental Medicine</i> , 2019 , 216, 476-478	16.6	6
210	ConvPath: A software tool for lung adenocarcinoma digital pathological image analysis aided by a convolutional neural network. <i>EBioMedicine</i> , 2019 , 50, 103-110	8.8	26
209	LCE: an open web portal to explore gene expression and clinical associations in lung cancer. <i>Oncogene</i> , 2019 , 38, 2551-2564	9.2	45
208	Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. <i>Cancer Research</i> , 2019 , 79, 125-132	10.1	31
207	Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis. <i>PLoS ONE</i> , 2019 , 14, e0208646	3.7	4

206	Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 150-157	12.9	7
205	Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. <i>Cell</i> , 2018 , 173, 864-878.e29	56.2	58
204	Evaluating tumor-suppressor gene combinations. <i>Nature Genetics</i> , 2018 , 50, 480-482	36.3	0
203	The Epithelial Sodium Channel (ENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors. <i>Translational Oncology</i> , 2018 , 11, 292-299	4.9	10
202	Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. <i>Cancer Research</i> , 2018 , 78, 1986-1999	10.1	7
201	Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. <i>Neoplasia</i> , 2018 , 20, 826-837	6.4	22
200	Kub5-Hera Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers. <i>Clinical Cancer Research</i> , 2018 , 24, 6459-6470	12.9	8
199	Retraction notice to "Sun exposure related methylation in malignant and non-malignant skin lesions" [Cancer Letters 245/1-2 (2007) 112-120]. <i>Cancer Letters</i> , 2018 , 432, 272	9.9	
198	TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. <i>Journal of Clinical Investigation</i> , 2018 , 128, 2500-2518	15.9	48
197	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). <i>Clinical Cancer Research</i> , 2018 , 24, 1038-1047	12.9	100
196	Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. <i>Translational Lung Cancer Research</i> , 2018 , 7, 32-49	4.4	88
195	A quantitative method for assessing smoke associated molecular damage in lung cancers. <i>Translational Lung Cancer Research</i> , 2018 , 7, 439-449	4.4	8
194	Transmembrane Protease TMPRSS11B Promotes Lung Cancer Growth by Enhancing Lactate Export and Glycolytic Metabolism. <i>Cell Reports</i> , 2018 , 25, 2223-2233.e6	10.6	19
193	LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. <i>Oncotarget</i> , 2018 , 9, 29601-29618	3.3	7
192	Different Originating Cells Underlie Intertumoral Heterogeneity in Lung Neuroendocrine Tumors. <i>Cancer Discovery</i> , 2018 , 8, 1216-1218	24.4	2
191	Estrogen Receptor Beta-Mediated Modulation of Lung Cancer Cell Proliferation by 27-Hydroxycholesterol. <i>Frontiers in Endocrinology</i> , 2018 , 9, 470	5.7	16
190	HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress. <i>Cancer Research</i> , 2018 , 78, 6196-6208	10.1	26
189	eIF2 α subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. <i>Cancer Science</i> , 2018 , 109, 1843-1852	6.9	13

188	Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 472-478	35.1	44
187	Identifying a missing lineage driver in a subset of lung neuroendocrine tumors. <i>Genes and Development</i> , 2018 , 32, 865-867	12.6	9
186	Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. <i>Cell Metabolism</i> , 2018 , 28, 369-382.e5	24.6	76
185	SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. <i>Nature Communications</i> , 2017 , 8, 14098	17.4	54
184	CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. <i>Cancer Research</i> , 2017 , 77, 3870-3884	19.1	107
183	Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	57
182	Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. <i>Cell Reports</i> , 2017 , 19, 1669-1684	10.6	55
181	CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. <i>Nature</i> , 2017 , 546, 168-172	50.4	136
180	The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. <i>Nature Communications</i> , 2017 , 8, 15503	17.4	79
179	Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer. <i>Cancer Science</i> , 2017 , 108, 732-743	6.9	11
178	Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers. <i>Cancer Research</i> , 2017 , 77, 3070-3081	10.1	26
177	Small-cell lung cancer: what we know, what we need to know and the path forward. <i>Nature Reviews Cancer</i> , 2017 , 17, 725-737	31.3	286
176	Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. <i>Oncotarget</i> , 2017 , 8, 11114-11126	3.3	16
175	Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties. <i>Cancer Prevention Research</i> , 2017 , 10, 514-524	3.2	6
174	Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer. <i>Journal of the American Society for Mass Spectrometry</i> , 2017 , 28, 2078-2089	3.5	11
173	PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis. <i>Cancer Research</i> , 2017 , 77, 187-197	10.1	33
172	Exosome mediated phenotypic changes in lung cancer pathophysiology. <i>Translational Cancer Research</i> , 2017 , 6, S1040-S1042	0.3	5
171	Developing EZH2-Targeted Therapy for Lung Cancer. <i>Cancer Discovery</i> , 2016 , 6, 949-52	24.4	21

170	Opening a Chromatin Gate to Metastasis. <i>Cell</i> , 2016 , 166, 275-276	56.2	3
169	Selecting Reliable mRNA Expression Measurements Across Platforms Improves Downstream Analysis. <i>Cancer Informatics</i> , 2016 , 15, 81-9	2.4	1
168	Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. <i>Radiation Research</i> , 2016 , 185, 527-381	3.1	9
167	Monitoring drug induced apoptosis and treatment sensitivity in non-small cell lung carcinoma using dielectrophoresis. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016 , 1860, 1877-83	4	21
166	An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 4880-4889	12.9	99
165	Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer. <i>Journal of Proteome Research</i> , 2016 , 15, 477-86	5.6	34
164	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 453-74	8.9	106
163	From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 287-99	8.9	37
162	Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non-Small Cell Lung Cancer and Its Potential as a Circulating Biomarker. <i>Cancer Prevention Research</i> , 2016 , 9, 43-52	3.2	24
161	ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3219-35	15.9	183
160	Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines. <i>PLoS ONE</i> , 2016 , 11, e0150963	3.7	11
159	Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. <i>Oncotarget</i> , 2016 , 7, 3548-58	3.3	89
158	Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1. <i>Oncotarget</i> , 2016 , 7, 30678-90	3.3	27
157	Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner. <i>Oncotarget</i> , 2016 , 7, 31639-51	3.3	29
156	MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016 , 11, e0150467	3.7	5
155	Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. <i>Cancer Cell</i> , 2016 , 30, 940-952	24.3	73
154	Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer. <i>Bioinformatics</i> , 2016 , 32, 1373-9	7.2	9
153	XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. <i>Nature</i> , 2016 , 538, 114-117	50.4	125

152	ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. <i>Cell Reports</i> , 2016 , 16, 1259-1272	10.6	193
151	Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. <i>Cell Reports</i> , 2016 , 16, 1614-1628	10.6	123
150	Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. <i>Cancer Discovery</i> , 2015 , 5, 860-77	24.4	476
149	Small cell lung cancer: will recent progress lead to improved outcomes?. <i>Clinical Cancer Research</i> , 2015 , 21, 2244-55	12.9	129
148	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. <i>Clinical Cancer Research</i> , 2015 , 21, 3480-91	12.9	36
147	Unbiased Selection of Peptide-Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells. <i>ACS Chemical Biology</i> , 2015 , 10, 2891-9	4.9	23
146	A systematic analysis reveals heterogeneous changes in the endocytic activities of cancer cells. <i>Cancer Research</i> , 2015 , 75, 4640-50	10.1	30
145	On comparing heterogeneity across biomarkers. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015 , 87, 558-67	4.6	10
144	Nuclear Receptor Expression and Function in Human Lung Cancer Pathogenesis. <i>PLoS ONE</i> , 2015 , 10, e0134842	3.7	11
143	Elucidation of changes in molecular signalling leading to increased cellular transformation in oncogenically progressed human bronchial epithelial cells exposed to radiations of increasing LET. <i>Mutagenesis</i> , 2015 , 30, 685-94	2.8	6
142	Molecular Basis of Lung Cancer 2015 , 475-490.e1		1
141	Genetic mutation of p53 and suppression of the miR-17~92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D Signaling. <i>Cancer Research</i> , 2015 , 75, 666-75	10.1	34
140	Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHCS. <i>Molecular Cancer Research</i> , 2015 , 13, 784-94	6.6	22
139	Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer. <i>Scientific Reports</i> , 2014 , 4, 4480	4.9	37
138	Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway. <i>Clinical Cancer Research</i> , 2014 , 20, 4154-66	12.9	108
137	ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 14788-93	11.5	144
136	Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	74
135	Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas. <i>Lung Cancer</i> , 2014 , 85, 282-92	5.9	18

134	A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets. <i>Cancer Research</i> , 2014 , 74, 4694-705	10.1	29
133	A pan-cancer proteomic perspective on The Cancer Genome Atlas. <i>Nature Communications</i> , 2014 , 5, 3887-9	17.4	324
132	Branching morphogenesis of immortalized human bronchial epithelial cells in three-dimensional culture. <i>Differentiation</i> , 2014 , 87, 119-26	3.5	24
131	Aiolos promotes anchorage independence by silencing p66Shc transcription in cancer cells. <i>Cancer Cell</i> , 2014 , 25, 575-89	24.3	49
130	NeuroD1 mediates nicotine-induced migration and invasion via regulation of the nicotinic acetylcholine receptor subunits in a subset of neural and neuroendocrine carcinomas. <i>Molecular Biology of the Cell</i> , 2014 , 25, 1782-92	3.5	11
129	Radiation-enhanced lung cancer progression in a transgenic mouse model of lung cancer is predictive of outcomes in human lung and breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 1610-22	12.9	21
128	Ras transformation uncouples the kinesin-coordinated cellular nutrient response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 10568-73	11.5	8
127	Comparison between concurrent and sequential chemoradiation for non-small cell lung cancer. <i>Oncology Letters</i> , 2014 , 7, 307-310	2.6	5
126	Adaptive prediction model in prospective molecular signature-based clinical studies. <i>Clinical Cancer Research</i> , 2014 , 20, 531-9	12.9	14
125	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1998-2006	27.4	1042
124	An innovative role of thyroid receptor β in triple-negative breast cancer (58.4). <i>FASEB Journal</i> , 2014 , 28, 58.4	0.9	
123	Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. <i>Cell</i> , 2013 , 155, 552-66	56.2	129
122	TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival. <i>Cancer Science</i> , 2013 , 104, 171-7	6.9	37
121	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. <i>Clinical Cancer Research</i> , 2013 , 19, 279-90	12.9	649
120	Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. <i>Molecular Cancer Research</i> , 2013 , 11, 638-50	6.6	135
119	A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. <i>Clinical Cancer Research</i> , 2013 , 19, 1577-86	12.9	182
118	IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2864-73	6.1	47
117	NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 6524-9	11.5	54

116	Molecular biology of lung cancer. <i>Journal of Thoracic Disease</i> , 2013 , 5 Suppl 5, S479-90	2.6	120
115	Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. <i>Nature Genetics</i> , 2012 , 44, 1111-6	36.3	712
114	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 228-39	9.7	331
113	Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. <i>Cancer Discovery</i> , 2012 , 2, 798-811	24.4	323
112	Use of proteomic analysis of LKB1/AMPK/mTOR pathways to identify IGF-1R pathway upregulation with LKB1 loss or mTOR inhibition in NSCLC: Implications for targeted combinations.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10612-10612	2.2	1
111	ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7589-7589	2.2	5
110	Investigation of PARP1 as a therapeutic target in small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7096-7096	2.2	
109	Effects of entinostat onresistance to cetuximab and EGFR TKIs in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e18077-e18077	2.2	1
108	Molecular biology of lung cancer: clinical implications. <i>Clinics in Chest Medicine</i> , 2011 , 32, 703-40	5.3	156
107	Multipotent capacity of immortalized human bronchial epithelial cells. <i>PLoS ONE</i> , 2011 , 6, e22023	3.7	51
106	Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells. <i>Cancer Science</i> , 2011 , 102, 1493-500	6.9	18
105	Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 336-46	6.1	123
104	A small-cell lung cancer genome with complex signatures of tobacco exposure. <i>Nature</i> , 2010 , 463, 184-90	90.4	852
103	Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. <i>Cancer Research</i> , 2010 , 70, 9937-48	10.1	314
102	A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. <i>Cancer Research</i> , 2010 , 70, 2359-67	10.1	40
101	Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. <i>Clinical Cancer Research</i> , 2010 , 16, 3743-53	12.9	315
100	Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. <i>PLoS Medicine</i> , 2010 , 7, e1000378	11.6	57
99	Lung cancer cell lines as tools for biomedical discovery and research. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1310-21	9.7	151

98	Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?. <i>Lung Cancer</i> , 2010 , 68, 309-18	5.9	81
97	Tumor oncogenotypes and lung cancer stem cell identity. <i>Cell Stem Cell</i> , 2010 , 7, 2-4	18	17
96	Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1894-904	8.9	50
95	Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. <i>Cancer and Metastasis Reviews</i> , 2010 , 29, 61-72	9.6	133
94	Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. <i>PLoS ONE</i> , 2010 , 5, e9112	3.7	110
93	Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. <i>Clinical Cancer Research</i> , 2009 , 15, 2666-74	12.9	66
92	Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. <i>PLoS ONE</i> , 2009 , 4, e4576	3.7	154
91	Haplotype and cell proliferation analyses of candidate lung cancer susceptibility genes on chromosome 15q24-25.1. <i>Cancer Research</i> , 2009 , 69, 7844-50	10.1	39
90	miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. <i>Molecular Cancer Research</i> , 2009 , 7, 1234-43	6.6	184
89	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. <i>Nature Genetics</i> , 2009 , 41, 1238-42	36.3	733
88	Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. <i>PLoS ONE</i> , 2009 , 4, e6146	3.7	537
87	Immortalization of human small airway epithelial cells with characteristics of bronchioalveolar stem cells. <i>FASEB Journal</i> , 2009 , 23, LB340	0.9	1
86	Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. <i>Cancer Research</i> , 2008 , 68, 1119-27	10.1	101
85	Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 14112-7	11.5	103
84	Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 41-7	12.9	61
83	Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer cells. <i>Cancer Research</i> , 2008 , 68, 8295-303	10.1	59
82	PIK3CA mutations and copy number gains in human lung cancers. <i>Cancer Research</i> , 2008 , 68, 6913-21	10.1	339
81	Synthetic lethal screen identification of chemosensitizer loci in cancer cells. <i>Nature</i> , 2007 , 446, 815-9	50.4	402

80	Characterizing the cancer genome in lung adenocarcinoma. <i>Nature</i> , 2007 , 450, 893-8	50.4	900
79	Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. <i>Cancer Research</i> , 2007 , 67, 709-17	10.1	41
78	Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. <i>PLoS Medicine</i> , 2007 , 4, e125	11.6	116
77	New molecularly targeted therapies for lung cancer. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2740-50	15.9	154
76	Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. <i>Cancer</i> , 2006 , 106, 2200-7	6.4	120
75	High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. <i>International Journal of Cancer</i> , 2006 , 118, 1556-64	7.5	110
74	EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 170-1		16
73	A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. <i>PLoS Medicine</i> , 2006 , 3, e486	11.6	191
72	Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. <i>Cancer Research</i> , 2006 , 66, 2116-28	10.1	223
71	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 31-37	8.9	16
70	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 31-37	8.9	13
69	A three-dimensional model of differentiation of immortalized human bronchial epithelial cells. <i>Differentiation</i> , 2006 , 74, 141-8	3.5	77
68	Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 6816-22	12.9	125
67	Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer. <i>Genes Chromosomes and Cancer</i> , 2005 , 44, 405-14	5	73
66	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. <i>Cancer Research</i> , 2005 , 65, 5561-70	10.1	285
65	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 339-46	9.7	1919
64	Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. <i>Cancer Research</i> , 2005 , 65, 226-35	10.1	270
63	Cancer. A bullseye for targeted lung cancer therapy. <i>Science</i> , 2004 , 304, 1458-61	33.3	74

62	Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. <i>Cancer Research</i> , 2004 , 64, 4277-85	10.1	156
61	Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. <i>Cancer Research</i> , 2004 , 64, 9027-34	10.1	498
60	Mutations and addiction to EGFR: the Achilles Heel of lung cancers?. <i>Trends in Molecular Medicine</i> , 2004 , 10, 481-6	11.5	251
59	A big step in the study of small cell lung cancer. <i>Cancer Cell</i> , 2003 , 4, 163-6	24.3	50
58	Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2003 , 107, 962-9	7.5	27
57	Molecular genetics of lung cancer. <i>Annual Review of Medicine</i> , 2003 , 54, 73-87	17.4	250
56	Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. <i>Journal of Clinical Investigation</i> , 2003 , 111, 31-3	15.9	62
55	Aberrant DNA methylation in lung cancer: biological and clinical implications. <i>Oncologist</i> , 2002 , 7, 451-7	5.7	115
54	Molecular pathogenesis of lung cancer. <i>Annual Review of Physiology</i> , 2002 , 64, 681-708	23.1	149
53	Focus on lung cancer. <i>Cancer Cell</i> , 2002 , 1, 49-52	24.3	367
52	Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2002 , 8, 2362-8	12.9	75
51	Molecular genetic abnormalities in the pathogenesis of human lung cancer. <i>Pathology and Oncology Research</i> , 2001 , 7, 6-13	2.6	56
50	Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. <i>Oncogene</i> , 2001 , 20, 1509-18	9.2	318
49	Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers. <i>Oncogene</i> , 2001 , 20, 1005-9	9.2	17
48	Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. <i>Oncogene</i> , 2001 , 20, 6258-62	9.2	70
47	Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 691-9	9.7	637
46	Molecular genetics of small cell lung carcinoma. <i>Seminars in Oncology</i> , 2001 , 28, 3-13	5.5	54
45	Two regions of homozygous deletion clusters at chromosome band 9p21 in human lung cancer. <i>Genes Chromosomes and Cancer</i> , 2000 , 27, 308-318	5	29

44	Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. <i>Genes Chromosomes and Cancer</i> , 2000 , 28, 359-69	5	19
43	Functional properties of a new voltage-dependent calcium channel alpha(2)delta auxiliary subunit gene (CACNA2D2). <i>Journal of Biological Chemistry</i> , 2000 , 275, 12237-42	5.4	131
42	Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1355-7	9.7	217
41	Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1303-7	9.7	302
40	Enrichment of epithelial cells for molecular studies. <i>Nature Medicine</i> , 1999 , 5, 459-63	50.5	61
39	Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. <i>Oncogene</i> , 1999 , 18, 643-50	9.2	286
38	Molecular pathogenesis of lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1999 , 118, 1136-52	5	101
37	Refined mapping of two regions of loss of heterozygosity on chromosome band 11q23 in lung cancer 1999 , 25, 154-159		23
36	Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. <i>Oncogene</i> , 1998 , 16, 3151-7	9.2	117
35	BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. <i>Oncogene</i> , 1998 , 16, 1097-112	9.2	545
34	Mutation analysis of the PTEN/MMAC1 gene in lung cancer. <i>Oncogene</i> , 1998 , 17, 1557-65	9.2	161
33	Homozygous deletions at 3p12 in breast and lung cancer. <i>Oncogene</i> , 1998 , 17, 1723-9	9.2	92
32	Progress in understanding the molecular pathogenesis of human lung cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1998 , 1378, F21-59	11.2	77
31	Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. <i>International Journal of Cancer</i> , 1998 , 78, 766-74	7.5	224
30	Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. <i>Genes Chromosomes and Cancer</i> , 1998 , 21, 308-19	5	138
29	The DUTT1 gene, a novel NCAM family member is expressed in developing murine neural tissues and has an unusually broad pattern of expression. <i>Molecular and Cellular Neurosciences</i> , 1998 , 11, 29-35	4.8	60
28	Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines. <i>Oncogene</i> , 1997 , 14, 1231-4	9.2	21
27	The human homolog of the rodent immediate early response genes, PC4 and TIS7, resides in the lung cancer tumor suppressor gene region on chromosome 3p21. <i>Human Genetics</i> , 1997 , 99, 334-41	6.3	22

26	Precise localization of the FHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines. <i>Genes Chromosomes and Cancer</i> , 1997 , 20, 16-23	5	21
25	NCI series of cell lines: an historical perspective. <i>Journal of Cellular Biochemistry</i> , 1996 , 24, 1-11	4.7	38
24	NCI-Navy Medical Oncology Branch cell line data base. <i>Journal of Cellular Biochemistry</i> , 1996 , 24, 32-91	4.7	215
23	Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. <i>Journal of Cellular Biochemistry</i> , 1996 , 24, 173-85	4.7	27
22	Karyotypic derivation of H9 cell line. <i>Journal of the National Cancer Institute</i> , 1993 , 85, 1168-9	9.7	4
21	Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1993 , 9, 33-43	5.7	52
20	Transcription factors and recessive oncogenes in the pathogenesis of human lung cancer. <i>International Journal of Cancer</i> , 1989 , 4, 32-4	7.5	13
19	Differential expression of myc family genes during murine development. <i>Nature</i> , 1986 , 319, 780-3	50.4	486
18	Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. <i>Nature</i> , 1985 , 316, 823-6	50.4	1240
17	L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. <i>Nature</i> , 1985 , 318, 69-73	50.4	556
16	The hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy. <i>Cancer</i> , 1985 , 55, 1429-35	6.4	12
15	The role of radiation therapy in the treatment of small cell lung cancer. <i>Cancer</i> , 1985 , 55, 2163-75	6.4	41
14	High-dose methotrexate with leucovorin rescue in patients with unresectable non-small cell carcinoma of the lung. <i>Cancer</i> , 1983 , 52, 1778-82	6.4	2
13	Amplification and expression of the c-myc oncogene in human lung cancer cell lines. <i>Nature</i> , 1983 , 306, 194-6	50.4	773
12	Abdominal computed tomography in small cell lung cancer: assessment of extent of disease and response to therapy. <i>Cancer</i> , 1982 , 49, 1485-90	6.4	14
11	Clinical implications of cytogenetic studies in cutaneous T-cell lymphoma (CTCL). <i>Cancer</i> , 1982 , 50, 1539-53	6.4	84
10	The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell subtypes. <i>Cancer</i> , 1982 , 50, 2894-902	6.4	149
9	Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide: methods of documenting tumor response and progression. <i>Cancer</i> , 1980 , 45, 1300-10	6.4	35

8	Evaluation of response to chemotherapy with fiberoptic bronchoscopy in non-small cell lung cancer. <i>Cancer</i> , 1980 , 45, 1693-6	6.4	6
7	CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. <i>Cancer</i> , 1979 , 44, 1885-93	6.4	404
6	Expression of feline xenotropic RNA tumor virus in hybrids between permissive human and non-permissive mouse cells. <i>International Journal of Cancer</i> , 1979 , 24, 826-34	7.5	7
5	The skin in disseminated intravascular coagulation. Prospective analysis of thirty-six cases. <i>British Journal of Dermatology</i> , 1973 , 88, 221-9	4	66
4	SCLC_CellMiner: Integrated Genomics and Therapeutics Predictors of Small Cell Lung Cancer Cell Lines based on their genomic signatures		1
3	Lineage transcription factors co-regulate subtype-specific genes providing a roadmap for systematic identification of small cell lung cancer vulnerabilities		3
2	Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells		1
1	Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer		2